Guide · Updated April 2026

Best GLP-1 for Women: Hormones, PCOS, and Menopause

Tirzepatide (Mounjaro, Zepbound) is the best GLP-1 for most women with PCOS based on clinical data: 22.5% average weight loss in SURMOUNT-1 vs. 14.9% for semaglutide in STEP 1, stronger insulin sensitization from dual GIP/GLP-1 action, and better lean mass preservation (34% of weight lost vs. 39-45% for semaglutide). For menopausal women, both medications work, but tirzepatide's superior fat loss and lower GI side effect rates make it the stronger starting option.

About 80% of women with PCOS are overweight or obese, and the condition is the leading cause of anovulatory infertility in the US. GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound) work by mimicking incretin hormones to reduce appetite, slow gastric emptying, and improve insulin sensitivity. For women dealing with hormonal weight gain, finding the best GLP-1 for women with PCOS or menopause-related metabolic changes is not just about the scale. It is about breaking a cycle of insulin resistance, androgen excess, and fat storage that standard diets rarely touch.

I have been on Mounjaro for over a year and track everything with DEXA scans. While my experience is not identical to a woman with PCOS or someone going through menopause, the body composition data I have collected lines up with what the clinical trials show: tirzepatide preserves more muscle and removes more fat than semaglutide, which matters enormously when hormones are already working against you.

Why Hormonal Weight Gain Responds Differently to GLP-1s

Standard weight loss advice fails most women with PCOS or menopause-related weight gain because it ignores the hormonal driver. Calorie restriction does not fix hyperinsulinemia. Cardio does not lower androgens. The weight comes back because the underlying metabolic problem never changed.

GLP-1 medications attack the root causes:

• Insulin resistance. Both semaglutide and tirzepatide improve insulin sensitivity directly, not just through weight loss. This matters because high insulin drives fat storage around the midsection and triggers excess androgen production in the ovaries.
• Androgen levels. By lowering insulin, GLP-1s reduce the signal that tells ovaries to produce excess testosterone. Multiple studies in women with PCOS show reduced free testosterone after GLP-1 treatment.
• Central adiposity. Women with PCOS store fat preferentially in the abdomen (visceral fat). GLP-1 medications target visceral fat more aggressively than subcutaneous fat, which is why the body composition changes on these drugs look different from typical diet weight loss.
• Appetite dysregulation. PCOS and menopause both increase hunger signaling through different mechanisms. GLP-1s act on the brain’s appetite centers to reduce food noise regardless of the hormonal cause.

For menopausal women, the picture is similar but the mechanism shifts. Estrogen decline redistributes fat from hips and thighs to the abdomen, increases insulin resistance, and reduces metabolic rate by roughly 50-100 calories per day. A GLP-1 will not replace estrogen, but it can counteract the metabolic consequences of losing it.

Tirzepatide vs Semaglutide for Women: Head-to-Head Data

The SURMOUNT-5 trial (NEJM, May 2025) gave us the first direct comparison of tirzepatide and semaglutide at maximum tolerated doses. While the trial was not women-specific, the results have clear implications for women dealing with hormonal weight challenges.

Three things stand out for women specifically:

1. Better muscle preservation. In SURMOUNT-1 (NEJM, July 2022), tirzepatide users lost about 34% of their total weight as lean mass, compared to 39-45% for semaglutide in STEP 1 (NEJM, February 2021). Women already lose muscle faster than men during weight loss, and menopause accelerates this further. Losing less lean mass means a better metabolic rate long-term and less risk of the frail, “skinny fat” outcome. Our muscle preservation protocol covers how to push these numbers even further with resistance training and protein.

2. Stronger insulin sensitization. Tirzepatide acts on both GIP and GLP-1 receptors. The GIP component adds extra insulin-sensitizing effects that matter for PCOS, where insulin resistance is the metabolic engine driving everything else. A meta-analysis of GLP-1 agonists in PCOS (BMC Endocrine Disorders, 2023, 11 RCTs, 840 patients) showed improved menstrual regularity, reduced androgens, and restored ovulation. Tirzepatide’s dual mechanism should amplify those benefits, though PCOS-specific head-to-head data is still pending.

3. Lower GI side effects. Nausea and vomiting are the most common reasons women stop GLP-1 treatment. In SURMOUNT-5, only 2.7% of tirzepatide users discontinued due to GI issues vs. 5.6% on semaglutide. If you have tried semaglutide and could not tolerate the nausea, switching to Mounjaro may be worth discussing with your provider.

Best GLP-1 for Women with PCOS

PCOS affects roughly 10% of women of reproductive age and is the most common cause of infertility linked to ovulation problems. The core issue is a feedback loop: insulin resistance drives androgen excess, androgens promote visceral fat storage, visceral fat worsens insulin resistance, and the cycle repeats.

GLP-1 medications break this loop at multiple points. The BMC Endocrine Disorders meta-analysis (2023) of 11 randomized controlled trials covering 840 women with PCOS found that GLP-1 receptor agonists improved body weight, BMI, fasting insulin, and testosterone levels. In one trial of 176 overweight women with PCOS, the pregnancy rate with exenatide (an older GLP-1) was 43.6% vs. 18.7% with metformin during the second treatment period.

Which GLP-1 to Choose for PCOS

Tirzepatide is the stronger choice for most women with PCOS. Here is why:

• The dual GIP/GLP-1 mechanism provides more potent insulin sensitization than semaglutide alone
• Greater total weight loss (22.5% at 15mg in SURMOUNT-1) means a higher chance of crossing the 5-10% threshold that restarts ovulation
• Better lean mass preservation protects metabolic rate during aggressive weight loss
• Lower nausea rates mean fewer dropouts and more consistent treatment

Semaglutide is still a good option if tirzepatide is unavailable or too expensive. At 14.9% average weight loss in STEP 1, semaglutide still produces enough weight reduction to significantly improve PCOS markers. It also has a longer track record in research, including more PCOS-specific studies.

PCOS-Specific Considerations

Fertility awareness. If you have PCOS and start a GLP-1, your fertility may improve faster than you expect. GLP-1 prescribing among women with PCOS increased from 2.4% in 2021 to 17.6% in 2025 (Truveta data), and “Ozempic babies” are a real phenomenon. Among patients who lost more than 5% body weight, 71% achieved normal menstrual cycles. Our fertility guide covers contraception concerns in detail, including the confirmed interaction between tirzepatide and oral birth control pills.

Metformin combination. Many women with PCOS are already on metformin. Adding a GLP-1 to metformin has shown better outcomes than either alone for both weight and reproductive markers. Combined metformin and semaglutide therapy outperformed metformin alone in recent studies. Talk to your prescriber about whether to continue metformin after starting a GLP-1.

Androgen monitoring. Ask your doctor to check free testosterone and DHEA-S before starting and at 3-6 month intervals. Watching androgens drop is one of the best indicators that the treatment is working at a hormonal level, not just on the scale.

Best GLP-1 for Women in Menopause

Menopause changes the weight loss equation. Estrogen decline after age 45-55 causes fat redistribution to the abdomen, increased insulin resistance, accelerated muscle loss (sarcopenia), and reduced resting metabolic rate. The average woman gains 5-8 pounds during the menopausal transition even without changing her eating habits.

Why GLP-1s Help During Menopause

GLP-1 medications address several menopause-specific metabolic problems:

• Visceral fat targeting. The belly fat that accumulates post-menopause is metabolically active visceral fat. GLP-1s reduce visceral fat more effectively than diet alone, which lowers cardiovascular risk independently.
• Insulin resistance. Post-menopausal insulin resistance responds well to GLP-1 treatment, even without estrogen replacement.
• Appetite changes. Many women report increased hunger and carbohydrate cravings during and after menopause. GLP-1s reduce appetite signaling in the hypothalamus regardless of estrogen status.

Tirzepatide vs Semaglutide for Menopausal Women

Both work. But for menopausal women, muscle preservation should be the deciding factor.

Women over 50 lose muscle at roughly 1-2% per year even without intentional weight loss. Adding a GLP-1 that takes 39-45% of weight from lean mass (semaglutide) vs. 34% (tirzepatide) can meaningfully accelerate age-related sarcopenia. Over 50 pounds of weight loss, that difference is 3-5 extra pounds of muscle preserved with tirzepatide.

Pair either medication with resistance training and adequate protein intake (at least 1g per pound of lean body mass). The body composition calculator can help you estimate your current lean mass and set targets. If you are losing weight and want to verify you are keeping muscle, a DEXA scan every 3-6 months is the gold standard. I wrote about my own DEXA results at six months for reference.

HRT and GLP-1s Together

Hormone replacement therapy (HRT) and GLP-1 medications are not mutually exclusive. Many women use both. HRT addresses the hormonal symptoms (hot flashes, sleep disruption, bone density loss, mood changes) while GLP-1s handle the metabolic and weight components. There are no known drug interactions between estrogen/progesterone HRT and semaglutide or tirzepatide.

If you are considering both, some telehealth providers now offer integrated menopause and weight management programs. Winona specializes in HRT for menopausal women and may be worth exploring alongside a GLP-1 provider.

Side Effects Women Should Watch For

GLP-1 side effects are generally similar across genders, but a few deserve extra attention for women.

Hair loss is the concern I hear about most from women on GLP-1s. It is almost always telogen effluvium triggered by rapid weight loss and caloric deficit, not a direct drug effect. It typically peaks 3-4 months after starting and resolves on its own. Our hair loss guide covers prevention strategies including protein targets and supplementation. Supplements that support hair and bone health matter more during menopause when baseline nutrient needs are already higher.

Gallbladder problems deserve attention because women are already at higher risk for gallstones, and rapid weight loss increases that risk further. The gallbladder guide covers warning signs and prevention.

For a full breakdown of what to expect month by month, see the side effects timeline guide.

How to Get Started: Cost and Access

GLP-1 medications are expensive at list price. Brand-name Wegovy runs $1,349/month and Zepbound $1,086/month before insurance. But real out-of-pocket costs vary widely.

Our cheapest GLP-1 guide has the full pricing breakdown across 73+ providers. If you have insurance, start with the insurance coverage guide to check whether your plan covers weight loss medications.

Many telehealth providers now specifically market to women. Calibrate includes metabolic testing and coaching. Found offers a lower-cost entry point. Ro and Hims serve both men and women with compounded options. Compare them all in the provider directory.

The Bottom Line

For women with PCOS, tirzepatide (Mounjaro/Zepbound) is the strongest GLP-1 option available based on weight loss data, insulin sensitization, lean mass preservation, and tolerability. Semaglutide (Ozempic/Wegovy) is a solid second choice, especially if cost or availability makes tirzepatide impractical. For menopausal women, the same ranking holds, with extra emphasis on pairing either medication with resistance training and protein to protect against age-related muscle loss.

Whichever GLP-1 you choose, the hormonal benefits go beyond the number on the scale. Lower insulin, reduced androgens, restored ovulation (for PCOS), and reduced visceral fat all improve long-term metabolic health in ways that calorie counting alone cannot match.

Start by comparing providers in the directory or use the body composition calculator to set a baseline before your first injection.

FAQ

What is the best GLP-1 for women with PCOS?

Tirzepatide (Mounjaro or Zepbound) is the best GLP-1 for most women with PCOS based on current data. It produces greater weight loss (22.5% at 15mg vs. 14.9% for semaglutide), stronger insulin sensitization through its dual GIP/GLP-1 mechanism, and better lean mass preservation. All three factors directly address the insulin-androgen cycle driving PCOS symptoms.

Can GLP-1 medications help with menopause weight gain?

Yes. GLP-1 medications effectively counter menopause-related weight gain by reducing appetite, improving insulin sensitivity, and targeting visceral fat accumulation. They do not replace estrogen or treat hot flashes, but they address the metabolic changes (increased insulin resistance, central fat redistribution) that drive post-menopausal weight gain.

Will a GLP-1 affect my period or fertility?

GLP-1 medications can restore regular menstrual cycles in women with PCOS. Among women who lost more than 5% body weight on GLP-1 treatment, 71% achieved normal cycles. This means fertility can improve quickly, sometimes within months. If you do not want to get pregnant, use a non-oral contraceptive method, especially on tirzepatide, which can reduce oral birth control absorption.

Is it safe to take a GLP-1 with HRT?

There are no known drug interactions between GLP-1 medications (semaglutide or tirzepatide) and standard hormone replacement therapy (estrogen, progesterone). Many menopausal women use both together. HRT addresses hormonal symptoms while the GLP-1 handles weight and metabolic health. Discuss the combination with your prescriber.

Do GLP-1 side effects differ for women?

The core side effects (nausea, constipation, diarrhea) are similar across genders, but women report higher rates of constipation and are 2-3x more likely to develop gallstones during rapid weight loss. Hair loss from caloric deficit is also more commonly reported by women. Nausea may fluctuate with the menstrual cycle. These effects are manageable with proper monitoring and dose titration.

Related

Guides:

• Cheapest GLP-1 Online · Insurance Coverage · Side Effects
• Muscle Preservation Protocol · Protein Intake on GLP-1s · Fat Loss vs Weight Loss
• Ozempic Baby and Fertility · DEXA Scan Results · Hair Loss

Provider Reviews: Ro · Hims · Calibrate · Found · Winona

Compare: All Providers · Best GLP-1 Programs · All Guides